Skip to content
value.today
Pliant Therapeutics, Inc. logo

Pliant Therapeutics, Inc.

Total raised
$163 M
2 rounds on record
Latest round
$100 M
Dec 2019
First round on record
Jul 2018
Today
Went public
See the company page

Pliant Therapeutics, Inc. is listed today as Pliant Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Pliant Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2019$100 MNo. 2$50 to $250 million

Pliant Therapeutics, Inc.: Raise no. 2, Dec 2019

Investors in this round

66 investors had bought by the notice of Mar 11, 2020: 66 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for Pliant Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$100 M of $100 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Barbara Howes · Executive Officer
  • Bernard Coulie · Executive Officer, Director
  • Eric Lefebvre · Executive Officer
  • Johannes Hull · Executive Officer
  • Keith Cummings · Executive Officer
  • Charles Homcy · Director
  • Gayle Crowell · Director
  • Hoyoung Huh · Director
  • John Curnutte · Director
  • Kevin Raidy · Director
  • Neil Exter · Director
  • Smital Shah · Director
  • Suzanne Bruhn · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Keith Cummings, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Mar 11, 2020. Read the notice at the SEC.

equitySEC
Jul 2018$62 MNo. 1$50 to $250 million

Pliant Therapeutics, Inc.: Raise no. 1, Jul 2018

Investors in this round

29 investors had bought by the notice of Jul 20, 2018: 29 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for Pliant Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$62 M of $62 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bernard Coulie · Executive Officer, Director
  • Eric Lefebvre · Executive Officer
  • Johannes Hull · Executive Officer
  • Charles Homcy · Director
  • Hoyoung Huh · Director
  • John Curnutte · Director
  • Kevin Raidy · Director
  • Neil Exter · Director
  • Suzanne Bruhn · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Johannes Hull, Secretary. Source: SEC Form D, newest notice filed Jul 20, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Pliant Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2020).

    SEC Form D · Mar 2020

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Mar 2020

That is all the official record says: Pliant Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Pliant Therapeutics, Inc. are on record.

Investors#

10 named in official filings. Open an investor to see everything it has backed.

Investors in Pliant Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Barbara HowesPersonnot statednot statedHeld Series C preferred stock (Form 3, 2020)SEC Form 3
Hans HullPersonnot statednot statedHeld Series B preferred stock (Form 3, 2020)SEC Form 3
Keith Lamont CummingsPersonnot statednot statedHeld Series C preferred stock (Form 3, 2020)SEC Form 3
Redmile Group, LLCFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Third Rock Ventures GP III, L.P.Venture capitalnot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Third Rock Ventures GP IV, L.P.Venture capitalnot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Third Rock Ventures III, L.P.Venture capitalnot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Third Rock Ventures IV, L.P.Venture capitalnot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2020)SEC Form 3
TRV GP III, LLCOthernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Trv Gp Iv, LLCFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2020)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 66 investors.

Largest shareholders today

Institutions holding Pliant Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Pliant Therapeutics, Inc.
NameRoleNamed in
Barbara HowesExecutive officerMar 2020
Bernard CoulieExecutive officerMar 2020
Eric LefebvreExecutive officerMar 2020
Johannes HullExecutive officerMar 2020
Keith CummingsExecutive officerMar 2020
Bernard CoulieDirectorMar 2020
Charles HomcyDirectorMar 2020
Gayle CrowellDirectorMar 2020
Hoyoung HuhDirectorMar 2020
John CurnutteDirectorMar 2020
Kevin RaidyDirectorMar 2020
Neil ExterDirectorMar 2020
Smital ShahDirectorMar 2020
Suzanne BruhnDirectorMar 2020

About

Company in South San Francisco, United States.

Went public since 2020. Its SEC number is that of a company listed on a stock exchange.